1292318-07-0

Basic information

• Product Name: (4-(2-chloropyrimidin-4-yl)aniline)
• Synonyms: (4-(2-chloropyrimidin-4-yl)aniline)
• CAS NO: 1292318-07-0
• Molecular Weight: 205.647
• Mol File: 1292318-07-0.mol

Chemical Properties

• CAS DataBase Reference: (4-(2-chloropyrimidin-4-yl)aniline)(CAS DataBase Reference)
• NIST Chemistry Reference: (4-(2-chloropyrimidin-4-yl)aniline)(1292318-07-0)
• EPA Substance Registry System: (4-(2-chloropyrimidin-4-yl)aniline)(1292318-07-0)

Safety Data

• Hazardous Substances Data: 1292318-07-0(Hazardous Substances Data)

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 214360-73-3 4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)aniline 

Downstream Products

• 1292318-08-1 N-[4-(2-chloropyrimidin-4-yl)phenyl]-2-methyl-propanamide 
• 69491-58-3 4-(4'-aminophenyl)pyrimidine 
• 945756-13-8 N-[4-(2-chloropyrimidin-4-yl)phenyl]acetamide 
• 1292318-11-6 ethyl 2-[4-[[4-[4-(2-methylpropanoylamino)phenyl]pyrimidin-2-yl]amino]phenyl]acetate 
• 1292318-12-7 2-[4-[[4-[4-(2-methylpropanoylamino)phenyl]pyrimidin-2-yl]amino]phenyl]acetic acid 

Relevant articles and documents

Computational design and discovery of nanomolar inhibitors of IκB kinase β

IκB kinase β (IKKβ) is a useful target for the discovery of new medicines for cancer and inflammatory diseases. In this study, we aimed to identify new classes of potent IKKβ inhibitors based on structure-based virtual screening, de novo design, and chemical synthesis. To increase the probability of finding actual inhibitors, we improved the scoring function for the estimation of the IKKβ-inhibitor binding affinity by introducing proper solvation free energy and conformational destabilization energy terms for putative inhibitors. Using this modified scoring function, we have been able to identify 15 submicromolar-level IKKβ inhibitors that possess the phenyl-(4-phenyl-pyrimidin-2-yl)-amine moiety as the molecular core. Decomposition analysis of the calculated binding free energies showed that a high biochemical potency could be achieved by lowering the desolvation cost and the conformational destabilization for the inhibitor required for binding to IKKβ as well as by strengthening the interactions in the ATP-binding site. The formation of two hydrogen bonds with backbone amide groups of Cys99 in the hinge region was found to be necessary for tight binding of the inhibitors in the ATP-binding site. From molecular dynamics simulations of IKKβ-inhibitor complexes, we also found that complete dynamic stability of the bidentate hydrogen bond with Cys99 was required for low nanomolar-level inhibitory activity. This implies that the scoring function for virtual screening and de novo design would be further optimized by introducing an additional energy term to measure the dynamic stability of the key interactions in enzyme-inhibitor complexes.

JAK Inhibitor with high oral bioavailability

The JAK inhibitor has high oral bioavailability, and is characterized in that the JAK inhibitor comprises a compound of the formula I, or a stereoisomer thereof. A geometric isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable salt

Small molecule compound serving as JAK kinase inhibitor and application of small molecule compound

The present invention provides a small molecule compound, which is a compound represented by the following formula, or a stereoisomer, a geometric isomer, a tautomer, a hydrate, a solvate, and a pharmaceutically acceptable salt or prodrug thereof, in whic

Optimization and biological evaluation of aminopyrimidine-based IκB kinase β inhibitors with potent anti-inflammatory effects

Targeting IκB kinase β (IKKβ) can be a promising strategy in the development of a therapeutic treatment of inflammatory diseases because IKKβ is well-recognized as a key mediator of the NF-κB signaling pathway. In this study, we have successfully develope

COMPOSITIONS AND THERAPEUTIC USES OF IKK-RELATED KINASE EPSILON AND TANKBINDING KINASE 1 INHIBITORS

The invention relates to compounds, pharmaceutical compositions and medicaments comprising such compounds, and the use of these compounds, compositions, and medicaments in methods of treating diseases and disorders.

AMINO - PYRIMIDINE COMPOUNDS AS INHIBITORS OF TBK1 AND/OR IKK EPSILON

The invention relates to certain aminopyrimidine compounds which inhibit TBK1 and/or IKK epsilon and which may therefore find application in treating inflammation, cancer, septic shock and/or Primary open Angle Glaucoma (POAG).